1. Home
  2. BEEP vs RNTX Comparison

BEEP vs RNTX Comparison

Compare BEEP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobile Infrastructure Corporation

BEEP

Mobile Infrastructure Corporation

HOLD

Current Price

$1.59

Market Cap

78.3M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.92

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEEP
RNTX
Founded
2015
2001
Country
United States
United States
Employees
N/A
10
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.3M
80.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BEEP
RNTX
Price
$1.59
$0.92
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$6.50
$10.00
AVG Volume (30 Days)
47.7K
609.8K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,075,000.00
N/A
Revenue This Year
$5.77
N/A
Revenue Next Year
$22.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.85
52 Week High
$4.67
$2.18

Technical Indicators

Market Signals
Indicator
BEEP
RNTX
Relative Strength Index (RSI) 33.06 45.01
Support Level N/A $0.85
Resistance Level $2.34 $1.33
Average True Range (ATR) 0.19 0.08
MACD -0.04 0.01
Stochastic Oscillator 6.40 54.47

Price Performance

Historical Comparison
BEEP
RNTX

About BEEP Mobile Infrastructure Corporation

Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: